ANIP News and Press, ANI Pharmaceuticals Inc. From 03/22/22

-- Dr. Tannenbaum’s successful track record in driving commercial excellence to contribute as Company executes Purified Cortrophin Gel TM launch -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced the addition of Renee P. Tannenbaum, P...

Lower oil prices and hope of a negotiated end to the conflict in Ukraine contributed to a stock rebound on Tuesday. The Nasdaq led the advance, climbing by about 2.9%, while the S&P 500 posted a gain of 2.1%. Airline stocks had a particularly strong day, bolstered by the drop in crude and...

ANI Pharmaceuticals, Inc. (ANIP) Q4 2021 Earnings Conference Call March 15, 2022, 08:30 ET Company Participants Judy DiClemente - IR Nikhil Lalwani - President, CEO & Director Stephen Carey - SVP, Finance & CFO Conference Call Participants Brandon Folkes - Cantor Fitzgerald & Co. ...

Gainers: Incannex Healthcare Limited (NASDAQ:IXHL) +176%. Revelation Biosciences (NASDAQ:REVB) +34%. Kaival Brands Innovations (NASDAQ:KAVL) +29%. Rapid Micro Biosystems (NASDAQ:RPID) +25%. Summer Infant (NASDAQ:SUMR) +22%. Kingsoft Cloud (NASDAQ:KC) +21%. RLX Technology (NYSE:RLX) +20%. Sone...

The shares of ANI Pharmaceuticals (ANIP -24.3%) have approached the lowest level since August after the maker of branded and generic medicines posted a lower than expected guidance for 2022. Net revenue for the quarter rose ~6% YoY to $60.9M as revenue from generic pharmaceuticals jumped...

Gainers: Incannex Healthcare IXHL +209%. Revelation Biosciences (NASDAQ:REVB) +25%. Co-Diagnostics CODX +14%. GreenLight Biosciences (NASDAQ:GRNA) +14%. Clearside Biomedical (NASDAQ:CLSD) +12%. Losers: Better Therapeutics BTTX -33%. ANI Pharmaceuticals ...

ANI Pharmaceuticals press release (NASDAQ:ANIP): Q4 GAAP EPS of $0.54 beats by $0.68. Revenue of $60.9M (+6.3% Y/Y) beats by $4.6M. Cash and cash equivalents were $100.3 million, net accounts receivable was $128.5 million, and face value of debt was $300.0 million as of December 31, 2021. Gui...

-- Fourth quarter net revenues of $60.9 million; net loss of $24.1 million and diluted loss per share of $1.72 -- -- Fourth quarter adjusted non-GAAP EBITDA of $16.2 million and adjusted non-GAAP diluted earnings per share of $0.54 -- -- Full year 2021 revenues of $216...

ANI Pharmaceuticals (NASDAQ:ANIP) is scheduled to announce Q4 earnings results on Tuesday, March 15th, before market open. The consensus EPS Estimate is $0.74 (-7.5% Y/Y) and the consensus Revenue Estimate is $56.3M (-1.7% Y/Y). Over the last 2 years, ANIP has beaten EPS estimates 63% of the ...

ANIP, ATNX, BBI, OTCQX:CCHWF, CTRN, DOLE, DTIL, GMDA, KMDA, KNDI, KPLT, NRP, OTCPK:RWEOY, SYRS For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Tuesday's open